Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 1/20 | 0.49 |
| ▸ | RORC | P51449 | 15/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3350252 | 0.85 | AQP1 (0.44) | AQP1RORCDRD2ABL1PDGFRB | |
| SCHEMBL13306787 | 0.82 | AQP1 (0.48) | AQP1RORCDRD2FGFR1LMNA | |
| SCHEMBL3347355 | 0.80 | AQP1 (0.54) | AQP1 | |
| SCHEMBL13306794 | 0.77 | AQP1 (0.43) | AQP1RORCDRD2ABL1PDGFRB | |
| SCHEMBL3343658 | 0.76 | AQP1 (0.51) | AQP1 | |
| SCHEMBL8228892 | 0.74 | DRD2 (0.43) | AQP1RORCDRD2FGFR1LMNA | |
| SCHEMBL5793270 | 0.73 | DRD2 (0.46) | AQP1RORCDRD2LMNAGAA | |
| SCHEMBL4959721 | 0.73 | AQP1 (0.74) | AQP1RORCLMNAGAA | |
| SCHEMBL4959730 | 0.73 | AQP1 (0.74) | AQP1RORCLMNAGAA | |
| SCHEMBL4230839 | 0.72 | AQP1 (0.72) | AQP1LMNAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2008052078-A2 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008052078-A2 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160411-A1 | BENZOXATHIINE AND BENZOXATHIOLE DERIVATIVES AND USES THEREOF | HTR2C, HTR3B, HTR1A | AQP1 2605/4885RORC 2648/4885DRD2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.